ClinicalTrials.govpublic full text
Risk Stratification and MRD-driven Maintenance for MM After ASCT
multiple myeloma, r2-iss stage, minimal residual disease, lenalidomide, daratumumab, interventional, na
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 868448
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.